New obesity may burn fat without suppressing appetite

While the injected GLP-1 drugs are incredibly effective in stimulating weight loss, they also come with some negative aspects. There can be intestinal side effects and muscle mass loss. Drugs are also expensive, at $ 1,000 per month or more in the United States before insurance. Pharmaceutical companies are interested in developing birth control pills because of their relatively cheap cost for manufacturing compared to injections, and the fact that some patients prefer to take birth control pills.

“There is still a clinical need that does not meet, and here Eolo wants to help,” says Maria Pia, CEO of the company.

Eolo was not completely initiated to make birth control pills. The company’s researchers were originally trying to develop a drug to target inflammation, especially the type that occurs in obesity and type 2 diabetes. But when they started testing their experimental medicine in mice, it was not limited to improving inflammation, but also led to a decrease in body weight while they were in a high -fat diet. They had experiences for nine months and found that mice eventually decreased to their weight even while they were still eating the same high -fat diet.

In mice, SANA also maintained the mass of the aging muscles. MRI tests show that mice treated with Sana have a larger percentage of lean body mass compared to controls, although large fat loss.

“We had steroids before trying to increase the product of calories,” said Hans Schmidt, head of obesity surgery and co -manager of the weight loss and metabolic health center at the Hekings University Medical Center, who did not participate in the study.

One of these was the group of phenfleusine-fentumine medications, known as Fein, which was sold in the 1990s for weight loss but was removed from the market to cause heart damage. “These are general metabolism. It makes you feel anxious, and makes you active. This seems to be specifically working on the cellular level on your fat cells,” he says.

Of course, the study of Eolo was very small, and the drug would need to test more people to better understand its effects. The company plans to experience the second stage later this year, which will include about 100 obese participants and follow them for 12 weeks. They hope to conduct this trial in the United States. GARAT eventually believes that Eolo can be used as an independent approach or in combination with GLP-1 medications to produce more weight loss.

“At the present time, we are bringing one of the tools with tools that we need many tools. We need more mechanisms that work on non -delicious paths,” says Angela Fitch, the former president of the Association of obesity and the founder of Cofner, a basic care company in obesity. Fitch is not involved with Eolo.

The current GLP-1 can achieve up to 20 percent of weight loss, and although this may be sufficient for some patients, others may still need to lose more to reach a healthy weight. “New medications, it provides the opportunity to make a greater effect,” she says.